8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Aug 27, 2018)

Filed August 27, 2018For Securities:ONCBEIGF

Summary

BeOne Medicines Ltd. (ONC), a biopharmaceutical company, announced a significant milestone on August 26, 2018, with the China Drug Administration (CDA) accepting its New Drug Application (NDA) for zanubrutinib. Zanubrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor being developed for patients suffering from relapsed/refractory mantle cell lymphoma (MCL). This acceptance by the CDA marks a crucial step in the drug development and commercialization process for BeOne Medicines, indicating that the regulatory authority will now review the application. Investors should monitor this development closely as it represents potential future revenue streams and a significant advancement in the company's pipeline, particularly in the oncology space.

Key Highlights

  • 1China Drug Administration (CDA) accepted the New Drug Application (NDA) for zanubrutinib.
  • 2Zanubrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor.
  • 3The NDA is for the treatment of relapsed/refractory mantle cell lymphoma (MCL).
  • 4This marks the first NDA acceptance for zanubrutinib by a major regulatory authority.
  • 5The press release detailing this announcement was issued on August 26, 2018.
  • 6The filing was made on August 27, 2018, as a Form 8-K.

Frequently Asked Questions

Zanubrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor. The New Drug Application (NDA) accepted by the China Drug Administration is for its use in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

The acceptance of the NDA by the China Drug Administration means that the regulatory authority will now formally review the application for zanubrutinib. This is a critical step in the drug approval process and indicates that zanubrutinib is progressing towards potential market approval in China.

The press release announcing the CDA's acceptance was issued on August 26, 2018. BeOne Medicines Ltd. subsequently filed this information with the SEC on August 27, 2018, via a Form 8-K Current Report.

The filing indicates that BeOne Medicines Ltd. is an emerging growth company, but it has not elected to use the extended transition period for complying with new or revised financial accounting standards.